PL3765055T3 - Peptydy wiążące bakterie do leczenia chorób zakaźnych i powiązanych procesów zapalnych - Google Patents

Peptydy wiążące bakterie do leczenia chorób zakaźnych i powiązanych procesów zapalnych

Info

Publication number
PL3765055T3
PL3765055T3 PL19710418.5T PL19710418T PL3765055T3 PL 3765055 T3 PL3765055 T3 PL 3765055T3 PL 19710418 T PL19710418 T PL 19710418T PL 3765055 T3 PL3765055 T3 PL 3765055T3
Authority
PL
Poland
Prior art keywords
bacterial
treatment
infectious diseases
binding peptides
inflammatory processes
Prior art date
Application number
PL19710418.5T
Other languages
English (en)
Inventor
Francisco Lozano Soto
Mario MARTÍNEZ FLORENSA
Original Assignee
Sepsia Therapeutics, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepsia Therapeutics, S.L. filed Critical Sepsia Therapeutics, S.L.
Publication of PL3765055T3 publication Critical patent/PL3765055T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • External Artificial Organs (AREA)
PL19710418.5T 2018-03-13 2019-03-13 Peptydy wiążące bakterie do leczenia chorób zakaźnych i powiązanych procesów zapalnych PL3765055T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382164 2018-03-13
PCT/EP2019/056315 WO2019175261A1 (en) 2018-03-13 2019-03-13 Bacterial-binding peptides for treatment of infectious diseases and related inflammatory processes

Publications (1)

Publication Number Publication Date
PL3765055T3 true PL3765055T3 (pl) 2023-11-27

Family

ID=61768231

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19710418.5T PL3765055T3 (pl) 2018-03-13 2019-03-13 Peptydy wiążące bakterie do leczenia chorób zakaźnych i powiązanych procesów zapalnych

Country Status (11)

Country Link
US (2) US11660326B2 (pl)
EP (1) EP3765055B9 (pl)
JP (1) JP7792115B2 (pl)
AU (1) AU2019233613B2 (pl)
CA (1) CA3133008A1 (pl)
ES (1) ES2953362T3 (pl)
HR (1) HRP20230984T1 (pl)
HU (1) HUE062829T2 (pl)
PL (1) PL3765055T3 (pl)
RS (1) RS64455B1 (pl)
WO (1) WO2019175261A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3541407A1 (en) * 2016-11-18 2019-09-25 Universitat de Barcelona Combined cd6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
PT4007777T (pt) 2019-08-02 2024-01-12 Hospital Cli­Nic De Barcelona Células car t contra bcma para o tratamento de mieloma múltiplo
US10881781B1 (en) 2020-04-29 2021-01-05 Orth Consulting, Llc Blood processing apparatus and method for detoxifying bacterial lipopolysaccharide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1274720A4 (en) * 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
ES2550389T3 (es) * 2007-03-28 2015-11-06 Universidad De Barcelona Producto de CD6 para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados
EP2714066B1 (en) * 2011-05-26 2017-04-05 Fundació Clínic per a la Recerca Biomèdica Soluble protein cd5 or cd6 for the treatment of cancer or tumor of for use as an adjuvant
BR112017010132B1 (pt) * 2014-11-17 2023-02-14 Entasis Therapeutics Limited Combinações e seus usos no tratamento de infecções bacterianas resistentes
EP3494136A1 (en) * 2016-08-04 2019-06-12 Oxford University Innovation Limited Chimeric antigen receptors
EP3541407A1 (en) * 2016-11-18 2019-09-25 Universitat de Barcelona Combined cd6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes

Also Published As

Publication number Publication date
HUE062829T2 (hu) 2023-12-28
HRP20230984T1 (hr) 2023-12-08
JP2021518426A (ja) 2021-08-02
AU2019233613A1 (en) 2020-10-29
WO2019175261A1 (en) 2019-09-19
AU2019233613B2 (en) 2025-02-13
EP3765055C0 (en) 2023-06-07
US11660326B2 (en) 2023-05-30
US20210023162A1 (en) 2021-01-28
CA3133008A1 (en) 2019-09-19
JP7792115B2 (ja) 2025-12-25
EP3765055B9 (en) 2023-09-27
EP3765055B1 (en) 2023-06-07
US20230381266A1 (en) 2023-11-30
RS64455B1 (sr) 2023-09-29
ES2953362T3 (es) 2023-11-10
EP3765055A1 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
IL269158A (en) Compositions and methods for treating inflammatory diseases
IL285269A (en) Compositions and methods for treating neurocognitive disorders
IL280563A (en) Anti-btn3a antibodies and their use in treating cancer or infectious disorders
IL272410A (en) Cytokine conjugates for the treatment of autoimmune diseases
IL285270A (en) Compositions and methods for treating neurocognitive disorders
IL284125A (en) Quinoline derivatives for use in the treatment of inflammation diseases
IL263174A (en) Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
PL3600309T3 (pl) Skojarzenia terapeutyczne do leczenia chorób wątroby
EP3359171C0 (en) Use of akkermansia muciniphila for treating inflammatory conditions
EP3538548A4 (en) IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
LT3774897T (lt) Pacientų, sergančių uždegiminėmis ligomis, atrankos ir gydymo būdai bei sistemos
IL287796A (en) Compositions and methods for the treatment of atpase-mediated diseases
MA49413A (fr) Traitement de gaz acide
IL273705B (en) Benzothiazol compounds and methods using the same for treating neurodegenerative disorders
EP3713955A4 (en) ANTI-IFNAR1 ANTIBODIES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
IL264070A (en) Methods and compositions for treatment of disorders and diseases involving rdh12
IL281244A (en) Combination therapy for the treatment of liver disease
ZA202101587B (en) Protein for treatment of inflammatory diseases
IL291192A (en) Compositions and methods of treating lupus nephritis
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
IL285268A (en) Compositions and methods for treating neurocognitive disorders
DK3761982T3 (da) Anvendelse af nalfurafin til behandling af demyeliniserende sygdomme
IL283039A (en) Immunogenic compositions for treatment of hepatitis b
HUE062829T2 (hu) Bakteriális összetevõt kötõ peptidek fertõzõ betegségek és kapcsolódó gyulladásos folyamatok kezelésére